Bionomics publishes resuls from Phase 2 ATTUNE study of BNC210
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Should l Buy ?
Bionomics Phase 2 Study Results: Bionomics announced positive results from its Phase 2 ATTUNE study published in NEJM Evidence, showing significant improvements in PTSD symptoms with BNC210 compared to placebo, including early improvements by Week 4.
Future Trials and Adverse Events: The company plans to initiate a Phase 3 trial for PTSD in late 2025 and is also conducting a Phase 3 study for social anxiety disorder, while noting treatment-emergent adverse events primarily included headache, nausea, and fatigue.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
